Toronto - Delayed Quote ? CAD Spectral Medical Inc. (EDT.TO) Follow Compare 0.5700 +0.0100 (+1.79%) At close: November 15 at 3:51 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Spectral Medical Third Quarter 2024 Earnings: CA$0.035 loss per share (vs CA$0.012 loss in 3Q 2023) Spectral Medical ( TSE:EDT ) Third Quarter 2024 Results Key Financial Results Revenue: CA$502.0k (up 26% from 3Q 2023... Simply Wall St. ? 9 days ago EDTXF -0.98% Hurricane Helene delays Spectral Medical’s confirmatory trial enrolment Spectral aims to finalise enrolment in early 2025 for its septic shock treatment Toraymyxin. Clinical Trials Arena ? 9 days ago EDTXF -0.98% Spectral Medical Announces Third Quarter Results and Provides Corporate Update Tigris Trial Enrollment at 135 PatientsStrengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter ended September 30, 2024, and provided a corporate update. Spectral has continued its significant progress throughout t GlobeNewswire ? 10 days ago EDTXF -0.98% Spectral Medical Provides October Tigris Trial Update ? 135 patients enrolled TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Robust enrollment continues for 202 GlobeNewswire ? 14 days ago EDTXF -0.98% Those who invested in Spectral Medical (TSE:EDT) three years ago are up 122% The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put... Simply Wall St. ? 17 days ago EDTXF -0.98% Spectral Medical Provides September Tigris Trial Update ? 132 patients enrolled TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Robust enrollment continues for 202 GlobeNewswire ? last month EDTXF -0.98% Spectral Medical Provides August Tigris Trial Update Management provides view on recently announced Vantive-Carlyle Group transactionTORONTO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shoc GlobeNewswire ? 2 months ago EDTXF -0.98% BAX CG Spectral Medical’s revenue up 54% as company eyes Tigris trial completion Spectral is already making plans for post FDA-approval, partnering with Baxter for commercialisation duties. Clinical Trials Arena ? 3 months ago EDTXF -0.98% Spectral Medical Second Quarter 2024 Earnings: CA$0.016 loss per share (vs CA$0.014 loss in 2Q 2023) Spectral Medical ( TSE:EDT ) Second Quarter 2024 Results Key Financial Results Revenue: CA$471.0k (up 54% from 2Q... Simply Wall St. ? 3 months ago EDTXF -0.98% Spectral Medical Announces Second Quarter Results and Provides Corporate Update Tigris Trial Enrollment Reaches 126 Patients Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2024, and provided a corporate update. Spectral has continued its significant progress throughout GlobeNewswire ? 3 months ago EDTXF -0.98% Spectral Medical Provides July Tigris Trial Update ? 125 patients enrolled? Record July patient enrollment to start the second half of 2024 TORONTO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and sep GlobeNewswire ? 3 months ago EDTXF -0.98% Spectral Medical Inc. Announces Closing of Additional US$1 Million Convertible Notes Large shareholder exercises anti-dilution pre-emptive rightsNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA. TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral") is pleased to announce the closing of an additional non-brokered offering of US$1 milli GlobeNewswire ? 3 months ago EDTXF -0.98% Spectral Medical Inc. Announces Change to Auditor TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that MNP LLP (“MNP”) have today been appointed as the auditors of the Company following the decision by PricewaterhouseCoopers LLP (“PwC”) to resign as the auditor of Spectral (the “Effective Date”). The resignation of PwC as the auditor of Spectral and the appointment of MNP as audit GlobeNewswire ? 4 months ago EDTXF -0.98% Spectral Medical Provides June Tigris Trial Update 116 patients enrolledJune represents a new record breaking month for patient enrollment TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and sept GlobeNewswire ? 4 months ago EDTXF -0.98% Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders TORONTO, June 07, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held earlier today (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 19, 2024 (the "Circular") to its Shareholders were approved. Results of t GlobeNewswire ? 5 months ago EDTXF -0.98% Shareholders May Be More Conservative With Spectral Medical Inc.'s (TSE:EDT) CEO Compensation For Now Key Insights Spectral Medical's Annual General Meeting to take place on 7th of June CEO Chris Seto's total compensation... Simply Wall St. ? 5 months ago EDTXF -0.98% Spectral Medical Inc. Announces Closing of Approximately C$8.5 Million?Convertible Notes Financing NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA. TORONTO, May 30, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral"), is pleased to confirm the closing of previously announced offering of 9% convertible notes of the Company at a price of US$1,000 per convertible no GlobeNewswire ? 5 months ago EDTXF -0.98% Spectral Medical First Quarter 2024 Earnings: CA$0.015 loss per share (vs CA$0.006 loss in 1Q 2023) Spectral Medical ( TSE:EDT ) First Quarter 2024 Results Key Financial Results Revenue: CA$668.0k (up 26% from 1Q 2023... Simply Wall St. ? 6 months ago EDTXF -0.98% Spectral Medical Announces First Quarter Results and Provides Corporate Update Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update. Spectral has continued its significant progress throughout the fi GlobeNewswire ? 6 months ago EDTXF -0.98% Spectral Medical Inc. Announces C$8.5 Million Bought Deal Convertible Note Financing NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA. TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral"), is pleased to announce that it has entered into an agreement with Paradigm Capital Inc. (the "Underwriter"), in connection with a bought deal priva GlobeNewswire ? 6 months ago EDTXF -0.98% Performance Overview Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return EDT.TO S&P/TSX Composite index YTD +34.12% +18.76% 1-Year +67.65% +24.31% 3-Year +103.57% +14.34%
